ipam

FLB-457 is a dopamine antagonist.

Etripamil (MSP-2017) displays atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells. Etripamil is an antagonist of short-acting L-type calcium-channel. It has a rapid onset of action designed for intranasal administration. It is also used to treat Paroxysmal Supraventricular Tachycardia.

Fipamezole is a potent alpha2 adrenergic receptor antagonist that may be useful for studying autonomic dysfunction in Parkinson's disease.

Iodipamide (Iodipamic acid) is a water-soluble radiographic contrast media for intravenous cholangiography and cholecystography.

Atipamezole is a synthetic α2 adrenergic receptor antagonist. It has also been researched in humans as a potential anti-Parkinsonian drug. Atipamezole hydrochloride (MPV-1248 hydrochloride) is hydrochloride form of atipamezole.

Ecopipam (UNII-0X748O646K) is a potent, selective, and orally active antagonist of dopamine D1 D5 receptors, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam demonstrates more than 40-fold selectivity over D2, D4, 5-HT, and α2a receptors (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). It is used in research on schizophrenia and obesity.

Adipamidoxime (NSC-70868) is an oxime-active compound that inhibits the growth of certain bacteria, fungi, and viruses and has some anti-inflammatory and anti-tumor activities.

Odapipam is a selective and high affinity antagonist of benzazepine dopamine D1 receptor (Kd of 0.18 nM).

Pipamperone (McN-JR 3345) binds 5-HT2A closely as receptor.

Anipamil is a long-acting blocker of calcium channel,and for the treatment of cardiovascular disease.

Xipamide (Diurexan) is a sulfonamide-based diuretic with antihypertensive properties. Xipamide selectively inhibits anion exchanger.

Etripamil (MSP-2017) hydrochloride is a fast-acting L-type calcium channel blocker used in the study of paroxysmal supraventricular tachycardia (PSVT). By inhibiting calcium ion influx through slow calcium channels, etripamil hydrochloride slows atrioventricular nodal conduction and extends the atrioventricular nodal refractory period.

Ronipamil is an analogue of verapamil that used as a calcium entry blocker.

Falipamil is a verapamil derivative and a calcium channel antagonist. Falipamil exerts antitachycardic effects by a direct action on the sinus node. Falipamil decreases HR at exercise in normal subjects and may exert antianginal effects in patients with m

Fipamezole HCl, a α2-adrenoceptor antagonist, is used potentially for the treatment of dyskinesia associated with Parkinson's disease.

Pipamperone acts as an antagonist of the 5-HT2A, 5-HT2B, 5-HT2C D2, D3, D4, α1-adrenergic, and α2-adrenergic receptors. It shows much higher affinity for the 5-HT2A and D4 receptors over the D2 receptor (15-fold in the case of the D4 receptor, and even hi

Alipamide is a bio-active chemical.

Tripamide is a type of diuretic.

Atipamezole (Antisedan) is a synthetic α2 adrenergic receptor antagonist. It has also been researched in humans as a potential anti-Parkinsonian drug.

Falipamil hydrochloride is a calcium channel antagonist potentially for the treatment of ischaemic heart disorder and sinus.

Berupipam is a dopamine D1 receptor antagonist.

Cipamfylline is a xanthine, a theophylline analogue, and is a potent and selective inhibitor of phosphodiesterase type 4 (PDE-4). Cipamfylline was tested in patients with a diagnosis of atopic dermatitis and in two human models of acute and chronic irritant contact dermatitis. The outcome of the study revealed that cipamfylline was more effective than vehicle in treating atopic dermatitis, but less effective than a group II steroid, hydrocortisone-17-butyrate both in the treatment of atopic dermatitis and irritant contact dermatitis. The absorption of cipamfylline and the subsequent systemic exposure might be the reason why further clinical studies with higher doses of cipamfylline have not been published.

Ecopipam (SCH 39166) hydrobromide is a highly potent, specific, and orally active dopamine D1 D5 receptor antagonist with K i values of 1.2 nM for D1 and 2.0 nM for D5 receptors. It shows over 40-fold greater selectivity for D1 D5 over D2, D4, 5-HT, and α2a receptors, with K i values of 0.98, 5.52, 0.08, and 0.73 μM, respectively, and is relevant for schizophrenia and obesity research.

Ipamorelin (NNC-26-0161) is a growth-hormone-releasing peptide, induces longitudinal bone growth in rats.